Wave Life Sciences, Inc.

WVE·NasdaqGM·Healthcare
Compare
3.6200+0.0400 (+1.12%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close3.5800
Open3.7000
Day range3.56003.7800
52-week range3.040021.7300
Off day high−4.23%
Off 52-week high−83.34%
Volume2.74M
Avg. volume (3M)3.32M
Market cap713.97M
EPS (TTM)-1.07
Forward P/E-3.08
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)-1.44
Shares outstanding197.23M
Short interest13.28% of float
Earnings dateOct 27, 2026
Analyst target17.1053
Profit margin−296.86%

Against its peers

Compare in full ›
WVE SLDB DSGN ARCT OBIO PRQR
Market cap 713.97M 699.11M 665.24M 308.96M 360.63M 198.98M
P/E (TTM) — — — — — —
Forward P/E -3.1 -3.8 -6.6 -2.9 -4.0 -3.0
Price/book 1.8 2.9 3.0 1.8 18.7 2.2
Dividend yield — — — — — —
1-year change −54.06% +54.69% +54.73% +31.12% +57.48% −42.44%
Today +1.12% +3.82% +2.80% +13.94% +7.91% +2.92%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All WVE news ›
ccua.org·Positive

Wave FCU Unleashes Support for The RI SPCA

On Saturday, September 14, 2024, Wave Federal Credit Union proudly sponsored the 22nd annual Paws in the Park, hosted at Goddard Memorial State Park in Warwick, RI. The event, benefiting the Rhode Island SPCA, attracted hundreds of…

WVE
Seeking Alpha··2 outletsPositive

Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings: dosing ongoing in…

WVE
More from 1 other outlet
markets.businessinsider.com·Positive

Wave Life Sciences (WVE) Receives a Buy from UBS

UBS analyst initiated coverage with a Buy rating on Wave Life Sciences today and set a price target of $11.00. Wave Life Sciences has an analy... UBS analyst initiated coverage with a Buy rating on Wave Life Sciences today and set a price…

WVE
markets.businessinsider.com·Positive

Wave Life Sciences initiated with an Outperform at William Blair

William Blair initiated coverage of Wave Life Sciences (WVE) with an Outperform rating. Wave is a clinical-stage RNA medicines company advancin... Wave Life Sciences initiated with an Outperform at William Blair William Blair initiated…

From the 4Search news index, newest first.

In the news

28mentions in 30 days
26with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance